Qu, Li, Tao, Ye, Huang, Chen, Xu, Jiang, Jia, & Xie (2026). Evaluation of the lipid accumulation product for MASLD risk stratification in type 2 diabetes: establishing sex-specific thresholds and clinical utility.. Cardiovascular diabetology.
Qu, Li, Tao, Ye, Huang, Chen, et al. Evaluation of the lipid accumulation product for MASLD risk stratification in type 2 diabetes: establishing sex-specific thresholds and clinical utility.. Cardiovascular diabetology. 2026; PMID: 42116040
Qu, Li, Tao, et al. Evaluation of the lipid accumulation product for MASLD risk stratification in type 2 diabetes: establishing sex-specific thresholds and clinical utility.[J]. Cardiovascular diabetology. 2026.
@article{qu2026,
author = {Qu and Li and Tao and Ye and Huang and Chen and Xu and Jiang and Jia and Xie},
title = {Evaluation of the lipid accumulation product for MASLD risk stratification in type 2 diabetes: establishing sex-specific thresholds and clinical utility.},
journal = {Cardiovascular diabetology},
year = {2026},
note = {PMID: 42116040},
}
TY - JOUR AU - Qu AU - Li AU - Tao AU - Ye AU - Huang AU - Chen AU - Xu AU - Jiang AU - Jia AU - Xie TI - Evaluation of the lipid accumulation product for MASLD risk stratification in type 2 diabetes: establishing sex-specific thresholds and clinical utility. T2 - Cardiovascular diabetology PY - 2026 AN - PMID:42116040 ER -
While visceral adiposity and lipid dysregulation are established drivers of metabolic dysfunction-associated steatotic liver disease (MASLD), the clinical utility of the lipid accumulation product (LAP) for identifying prevalent MASLD in patients with type 2 diabetes mellitus (T2DM) remains insufficiently characterized. This study aimed to characterize the dose-response relationship between LAP and MASLD in T2DM, establish optimal sex-specific diagnostic thresholds, and evaluate its clinical net benefit to guide non-invasive screening.